代谢体学市场规模、份额、成长分析、按产品、按生物资讯学工具和服务、按应用、按适应症、按最终用户、按公司类型、按地区 - 2025 年至 2032 年行业预测

2023 年代谢体学市场规模价值为 41 亿美元，预计将从 2024 年的 46.7 亿美元成长到 2032 年的 131.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 13.8%。

由于代谢组学在精准医疗中的应用日益广泛以及慢性病诊断方法的不断发展，代谢体学市场预计将显着增长。主要驱动因素包括製药领域研发投入的增加和分析技术的进步，特别是核磁共振波谱和质谱技术，使得能够对各种生物样本中的代谢物进行全面的分析。这种复杂性将有助于更好地了解与糖尿病、心臟病和癌症等疾病相关的代谢异常。透过揭示个体的代谢特征，代谢体学可以促进个体化医疗，从而实现更好的疾病预测和个人化的管理策略。随着研究发现新的代谢物和相互作用，对标靶和非标靶代谢体学服务的需求将会增加，巩固代谢体学在医疗保健创新中的重要性。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

代谢体学市场规模（按产品和复合年增长率） (2025-2032)

• 市场概况
• 代谢体学学仪器
• 隔离工具
  • 气相层析法
  • 高效液相层析
  • 超高效液相层析
  • 毛细管电泳
• 发现工具
  • 核磁共振（NMR）光谱
  • 质谱法（MS）
  • 基于表面的质谱分析

代谢体学市场规模（依生物资讯工具及服务划分）及复合年增长率（2025-2032）

• 市场概况
• 生物资讯服务
• 生物资讯工具和资料库

代谢体学市场规模（按应用和复合年增长率） (2025-2032)

• 市场概况
• 生物标记发现
• 药物研发
• 毒性测试
• 营养基因体学
• 功能基因体学
• 个人化医疗
• 其他用途

代谢体学市场规模（按适应症和复合年增长率） (2025-2032)

• 市场概况
• 癌症
• 心血管疾病
• 神经系统疾病
• 代谢紊乱
• 先天性代谢缺陷
• 其他适应症

代谢体学市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概况
• 学术研究所
• 製药和生物技术公司
• 合约研究组织
• 其他最终用户

代谢体学市场规模（按公司类型和复合年增长率） (2025-2032)

• 市场概况
• 层级製药公司
• 层级製药公司
• 层级製药公司

代谢体学市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Agilent Technologies, Inc.（US）
• Thermo Fisher Scientific, Inc.（US）
• Waters Corporation（US）
• Bruker Corporation（US）
• Shimadzu Corporation（Japan）
• Danaher Corporation（SCIEX）（US）
• PerkinElmer, Inc.（US）
• Merck KGaA（Germany）
• Bio-Rad Laboratories, Inc.（US）
• Metabolon, Inc.（US）
• LECO Corporation（US）
• Human Metabolome Technologies, Inc.（Japan）
• GL Sciences, Inc.（Japan）
• Bioocrates Life Sciences AG（Austria）
• BASF SE（Germany）
• MS-OMICS（Various locations）
• Afekta Technologies Ltd.（Finland）
• DNA Xperts Private Limited.（India）
• Metabolomic Technologies Inc.（Canada）
• Kore Technology Ltd.（UK）

结论和建议

Metabolomics Market size was valued at USD 4.1 billion in 2023 and is poised to grow from USD 4.67 billion in 2024 to USD 13.12 billion by 2032, growing at a CAGR of 13.8% during the forecast period (2025-2032).

The metabolomics market is poised for significant growth due to its increasing adoption in precision medicine and evolving diagnostics for chronic conditions. Key drivers include rising R&D investments in the pharmaceutical sector and advancements in analytical techniques, particularly nuclear magnetic resonance spectroscopy and mass spectrometry, which enable the comprehensive analysis of metabolites in various biological samples. This sophistication enhances our understanding of metabolic dysregulation associated with diseases like diabetes, heart disease, and cancer. By revealing individual metabolic signatures, metabolomics facilitates tailored medical care, enabling better disease prediction and personalized management strategies. As research uncovers novel metabolites and interactions, the demand for targeted and untargeted metabolomics services is set to rise, solidifying its importance in healthcare innovation.

Top-down and bottom-up approaches were used to estimate and validate the size of the Metabolomics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Metabolomics Market Segments Analysis

Global Metabolomics Market is segmented by Product, Bioinformatics Tools and Services, Application, Indication, End User, Company Type and region. Based on Product, the market is segmented into Metabolomics Instruments, Separation Tools and Detection Tools. Based on Bioinformatics Tools and Services, the market is segmented into Bioinformatics Services and Bioinformatics Tools and Databases. Based on Application, the market is segmented into Biomarker discovery, Drug discovery, Toxicology testing, Nutrigenomics, Functional Genomics, Personalized medicine and Other Applications. Based on Indication, the market is segmented into Cancer, Cardiovascular Disorders, Neurological Disorders, Metabolic Disorders, Inborn Errors of Metabolism and Other Indications. Based on End User, the market is segmented into Academic and Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Other End Users. Based on Company Type, the market is segmented into Tier 1 Pharmaceutical Companies, Tier 2 Pharmaceutical Companies and Tier 3 Pharmaceutical Companies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Metabolomics Market

Metabolite profiling within biological matrices plays a crucial role in discovering biomarkers and advancing personalized medicine. Through metabolomics studies, researchers can identify various biomarkers associated with intricate clinical phenotypes across multiple biological systems. This process is instrumental in the development of tailored medical treatments, focusing on optimizing therapeutic effectiveness while addressing potential toxicity issues. By employing metabolomics, healthcare providers can enhance patient outcomes by ensuring that medical interventions are more aligned with individual biological responses, ultimately paving the way for a more personalized approach to healthcare.

Restraints in the Metabolomics Market

The Metabolomics market faces significant restraints due to the rapid increase in high-volume and heterogeneous data generation, which exacerbates the existing complexity surrounding data management. As life science research produces increasingly intricate and multifaceted data, accurately evaluating high-dimensional information becomes a daunting challenge. This heightened complexity is anticipated to hinder the growth of the Metabolomics market, as researchers and organizations struggle to effectively analyze and interpret the data generated. Consequently, the difficulty in managing such complicated datasets may limit advancements and adoption within the sector, ultimately restraining its potential expansion and innovation.

Market Trends of the Metabolomics Market

The Metabolomics market is witnessing a significant upward trend driven by the expanding applications of biomarkers derived from bioinformatics analyses. As healthcare increasingly pivots towards personalized medicine, the identification of novel biomarkers through metabolomics advancements is becoming essential for in-vitro diagnostics, environmental toxicology assessment, and drug discovery processes. Over the past decade, the "omics" revolution has not only enhanced the technical capabilities of metabolomics but also broadened its relevance across various biomedical domains. This growth trajectory is expected to continue, fueled by the rising demand for precision medicine and integrative approaches to health diagnostics, propelling the Metabolomics market into new horizons of innovation and application.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Metabolomics Market Size by Product & Service & CAGR (2025-2032)

• Market Overview
• Metabolomics Instruments
• Separation Tools
  • Gas Chromatography
  • High-performance Liquid Chromatography
  • Ultra-performance Liquid Chromatography
  • Capillary Electrophoresis
• Detection Tools
  • Nuclear Magnetic Resonance (NMR) Spectroscopy
  • Mass Spectrometry (MS)
  • Surface-Based Mass Analysis

Global Metabolomics Market Size by Bioinformatics Tools and Services & CAGR (2025-2032)

• Market Overview
• Bioinformatics Services
• Bioinformatics Tools and Databases

Global Metabolomics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Biomarker discovery
• Drug discovery
• Toxicology testing
• Nutrigenomics
• Functional Genomics
• Personalized medicine
• Other Applications

Global Metabolomics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Cancer
• Cardiovascular Disorders
• Neurological Disorders
• Metabolic Disorders
• Inborn Errors of Metabolism
• Other Indications

Global Metabolomics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Academic and Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Other End Users

Global Metabolomics Market Size by Company Type & CAGR (2025-2032)

• Market Overview
• Tier 1 Pharmaceutical Companies
• Tier 2 Pharmaceutical Companies
• Tier 3 Pharmaceutical Companies

Global Metabolomics Market Size & CAGR (2025-2032)

• North America (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
  • US
  • Canada
• Europe (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product & Service, Bioinformatics Tools and Services, Application, Indication, End User, Company Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Waters Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bruker Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shimadzu Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (SCIEX) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabolon, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LECO Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Human Metabolome Technologies, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GL Sciences, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioocrates Life Sciences AG (Austria)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BASF SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MS-OMICS (Various locations)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Afekta Technologies Ltd. (Finland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DNA Xperts Private Limited. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabolomic Technologies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kore Technology Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations